← Leaderboards
Sang Pil Yoo
University Of California Los Angeles
$140,850
Attributed
$140,850
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $54.5K · FY2023–25$100K$75K$50K$25K$0
'23
'24
'25
Funding mix
By agency
NIH$140,850 · 1
By mechanism
F30$140,850 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Kristina I Bostrom$17,274,164
- Linda M Liau$8,990,878
- Jerome A. Zack$38,514,975
- Theodore Scott Nowicki$1,557,062
- Sherie L Morrison$12,725,119
Others in their field
Other Rising Stars on “Crispr/Cas Technology”
- Christopher W Peterson · Fred Hutchinson Cancer Center$4,692,222
- Xu Chen · University Of California, San Francisco$3,581,285
- Courtney Cohen · Albert Einstein College Of Medicine$3,541,248
- Amar Nijagal · University Of California, San Francisco$3,176,680
- Hao Li · Salk Institute For Biological Studies$2,988,273
- Allison Mercedes Caban-Holt · University Of Miami School Of Medicine$2,611,182
Research focus
Crispr/Cas Technology3&Apos3-DimensionalAntigensAutologousAffectCancer TypeAllogenicCd19 GeneCd4 Positive T LymphocytesCd8b1 GeneCd8-Positive T-LymphocytesBiologicalCell MaturationCellsCell TherapyCellular BiologyCar T Cell TherapyChimeric Antigen ReceptorChimeric Antigen Receptor T CellsClinical CareConstitutive ExpressionCostCytotoxicity
Grant awards (3)
Engineering detours around the biologic barriers to allogeneic, iPSC-derived CAR T immunotherapy$54,538
F30 · FY2025 · CA · contact PI
Engineering detours around the biologic barriers to allogeneic, iPSC-derived CAR T immunotherapy$43,796
F30 · FY2024 · CA · contact PI
Engineering detours around the biologic barriers to allogeneic, iPSC-derived CAR T immunotherapy$42,516
F30 · FY2023 · CA · contact PI